Safety of Intrathecal Rituximab as Prophylaxis or Treatment in CD20+ Acute Lymphoblastic Leukemia (ALL) and Aggressive Lymphoma (AL): Report from a Mexican Pilot Study

Reviewer: John P. Plastaras, MD, PhD
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 22 de marzo del 2007

Translation for this article does not exist

Blogs

Cancer and Hair Loss
by Bob Riter
February 11, 2016